ESR1 and breast neoplasm: We also identified that in human breast tumors, nuclear colocalization of PR and activated c-Jun is a novel marker of better overall survival (OS) in patients receiving anti-estrogen receptor (ER) therapy with tamoxifen (Tam) and revealed a new mechanism underlying Tam resistance.